Previous 10 | Next 10 |
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NERLYNX® (neratinib) for the treatment of breast cancer patients with brain metastases. “Receiving Orphan Drug Designation from the FDA s...
August 12, 2019 Palm Beach, FL – August 12, 2019 – Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market...
Gainers: Arcadia Biosciences (NASDAQ: RKDA ) +123% . Two River Bancorp (NASDAQ: TRCB ) +46% . InnerWorkings (NASDAQ: INWK ) +45% . Cutera (NASDAQ: CUTR ) +30% . PCTEL (NASDAQ: PCTI ) +24% . iFresh (NASDAQ: IFMK ) +21% . Puma Biotechnology (NASDAQ: PBYI ) +20% . China Natural R...
Arcadia Biosciences (NASDAQ: RKDA ) +62% on USDA OK of drought-tolerant soybean strain. More news on: Arcadia Biosciences, Inc., Puma Biotechnology, Inc., Callaway Golf Company, Stocks on the move, Read more ...
Start Time: 16:30 End Time: 17:23 Puma Biotechnology, Inc. (PBYI) Q2 2019 Earnings Conference Call August 08, 2019, 16:30 PM ET Company Participants Alan Auerbach - Chairman, President and CEO Steve Lo - COO Maximo Nougues - CFO Mariann Ohanesian - Senior Director, IR Co...
The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Puma Biotechnology (NASDAQ: PBYI ) Q2 results : More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Puma Biotechnology (NASDAQ: PBYI ): Q2 Non-GAAP EPS of -$0.57 beats by $0.42 ; GAAP EPS of -$0.97 beats by $0.02 . Revenue of $53.9M (+6.1% Y/Y) beats by $0.5M . Shares +0.1% . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stocks...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019. Unless otherwise stated, all comparisons are for the second quarter 2019 compared to the second quarter of 2018. Product revenue, net consists enti...
Puma Biotechnology ( PBYI -3.2% ) slips on below-average in apparent response to results from a Phase 3 clinical trial evaluating Merck's Keytruda (pembrolizumab) for the treatment of triple-negative breast cancer (TNBC) in an adjuvant setting. More news on: Puma Biotechnology, Inc., H...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...